腹膜后肿瘤的病理诊断与鉴别诊断 - 开云网页登录

主管：开云网页登录
主办：开云网页登录医学院附属瑞金医院
ISSN 1007-9610 CN 31-1758/R

外科理论与实践››2022,Vol. 27››Issue (06): 500-505.doi:10.16139/j.1007-9610.2022.06.04

• 专家论坛 •上一篇下一篇

腹膜后肿瘤的病理诊断与鉴别诊断

王坚()

复旦大学附属肿瘤医院病理科，上海 200032

收稿日期:2022-09-26出版日期:2022-11-25发布日期:2023-01-30
通讯作者:王坚，E-mail: softtissuetumor@163.com

Retroperitoneal tumor: pathological diagnosis and differential diagnosis

WANG Jian()

Received:2022-09-26Online:2022-11-25Published:2023-01-30

摘要/Abstract

中图分类号:

王坚. 腹膜后肿瘤的病理诊断与鉴别诊断[J]. 外科理论与实践, 2022, 27(06): 500-505.

WANG Jian. Retroperitoneal tumor: pathological diagnosis and differential diagnosis[J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 500-505.

图/表3

表1

SFT转移风险分层模型

风险因素	评分（分）	5年；10年无转移率
年龄（岁）
<55	0
≥55	1
肿瘤直径（cm）
<5	0
5~<10	1
10~<15	2
≥15	3
核分裂相（/10高倍视野）
0	0
1~3	1
≥4	2
肿瘤坏死
<10%	0
≥10%	1
风险分层	合计
低	0~3	100%
中	4~5	69%；50%
高	6~7	0；0

表1

表2

表3

参考文献14

[1]	Messiou C, Moskovic E, Vanel D, et al. Primary retroperitoneal soft tissue sarcoma: imaging appearances, pitfalls and diagnostic algorithm[J]. Eur J Surg Oncol, 2017, 43(7):1191-1198. doi:S0748-7983(16)31010-1pmid:28057392
[2]	Makise N, Yoshida A, Komiyama M, et al. Dedifferentia-ted liposarcoma with epithelioid/epithelial features[J]. Am J Surg Pathol, 2017, 41(11):1523-1531. doi:10.1097/PAS.0000000000000910 URL
[3]	Agaimy A, Michal M, Hadravsky L, et al. Dedifferentia-ted liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant[J]. Hum Pathol, 2018, 77:20-27. doi:S0046-8177(17)30496-3pmid:29307627
[4]	Saada-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas[J]. Mod Pathol, 2015, 28(11):1404-1414. doi:10.1038/modpathol.2015.96 URL
[5]	Schaefer IM, Lundberg MZ, Demicco EG, et al. Relationships between highly recurrent tumor suppressor alte-rations in 489 leiomyosarcomas[J]. Cancer, 2021, 127(15):2666-2673. doi:10.1002/cncr.33542 URL
[6]	Pérot G, Derré J, Coindre JM, et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas[J]. Cancer Res, 2009, 69(6):2269-2278. doi:10.1158/0008-5472.CAN-08-1443pmid:19276386
[7]	Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased posto-perative primary desmoid tumor recurrence: an independent, multicenter validation study[J]. Cancer, 2013, 119(20):3696-3702. doi:10.1002/cncr.28271pmid:23913621
[8]	Demicco EG, Wagner MJ, Maki RG, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model[J]. Mod Pathol, 2017, 30(10):1433-1442. doi:10.1038/modpathol.2017.54 URL
[9]	Tanaka T, Masumori N. Current approach to diagnosis and management of retroperitoneal fibrosis[J]. Int J Urol, 2020, 27(5):387-394. doi:10.1111/iju.14218pmid:32166828
[10]	徐静, 张勇, 童汉兴, 等. 静脉内平滑肌瘤病的临床特征与外科治疗策略[J]. 中国临床医学, 2019, 26(3):369-373.
[11]	Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma[J]. Cancer Cell, 2017, 31(2):181-193. doi:S1535-6108(17)30001-6pmid:28162975
[12]	Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma[J]. J Intern Med, 2019, 285(2):187-204. doi:10.1111/joim.12869pmid:30536464
[13]	Burgues O, Navarro S, Noguera R, et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma(Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry[J]. Virchows Arch, 2006, 449(4):410-420. doi:10.1007/s00428-006-0253-y URL
[14]	Hoshino Y, Yamada I, Shimano SI. Malignant lymphoma mimicking retroperitoneal fibrosis[J]. Intern Med, 2021, 60(20):3345-3346. doi:10.2169/internalmedicine.7142-21 URL

相关文章1

编辑推荐

Metrics

本文评价